Sunday - June 2, 2024

Antisense Oligonucleotides Targeting SCN2A for the Treatment of SCN1A Encephalopathies

2024-03-26

ALEXANDRIA, Virginia, March 26 -- ROGCON, INC., Miami Beach, Florida has been assigned a patent (No. US 11939582 B2, initially filed Aug. 20, 2019) developed by Steven Petrou, Eltham, Australia, for "Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Antisense Oligonucleotides Targeting SCN2A for the Treatment of SCN1A Encephalopathies

Information Request Form

Copyright Targeted News Service 2024